CDC recommends Morgan Stanley as a catalyst, optimistic about the prospects of Gilead's HIV new drug market, reiterating a "buy" rating.

Morgan Stanley analyst Terence Flynn published a research report, reiterating a "buy" rating on Gilead Sciences, Inc. (GILD.US) and setting a target price of $143. The analyst pointed out that the Centers for Disease Control and Prevention (CDC) in the United States has recently included Gilead's Yeztugo drug in its recommendations for pre-exposure prophylaxis for HIV. Flynn believes that this recommendation is an authoritative recognition of the drug's efficacy and safety. Additionally, he also stated that the CDC's recommendation is expected to improve patient medication adherence, enhance HIV prevention effects, and further drive market demand growth for Yeztugo. Meanwhile, Gilead Sciences, Inc. is actively advancing commercial insurance coverage plans for Yeztugo, and it is expected to receive broad insurance reimbursement support by the end of 2025. As a biopharmaceutical company, Gilead Sciences, Inc. focuses on developing drugs for the treatment of major diseases, with research areas including HIV, viral hepatitis, COVID-19, and cancer, among others.